HT
ALXN

HAP Trading’s Alexion Pharmaceuticals ALXN Stock Holding History

HAP Trading’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,700
Closed -$217K – 2761
2020
Q4 		$217K Buy
+7,700
New +$989K 0.01% 928
2020
Q1 		– Sell
-12,200
Closed -$53K – 1607
2019
Q4 		$53K Buy
+12,200
New +$1.3M ﹤0.01% 697
2018
Q3 		– Sell
-294,000
Closed -$514K – 1227
2018
Q2 		$514K Sell
294,000
-99,300
-25% -$11.6M 0.03% 322
2018
Q1 		$804K Buy
+393,300
New +$47M 0.04% 263
2017
Q4 		– Sell
-112,900
Closed -$1.25M – 1218
2017
Q3 		$1.25M Sell
112,900
-208,400
-65% -$28.3M 0.06% 217
2017
Q2 		$971K Buy
321,300
+84,900
+36% +$9.88M 0.05% 263
2017
Q1 		$245K Buy
236,400
+209,100
+766% +$27M 0.02% 452
2016
Q4 		$40K Buy
27,300
+16,300
+148% +$1.99M ﹤0.01% 680
2016
Q3 		$19K Buy
+11,000
New +$1.42M ﹤0.01% 885
2013
Q4 		– Sell
-333,200
Closed -$617K – 1392
2013
Q3 		$617K Buy
+333,200
New +$36.6M 0.02% 483

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAP Trading's ALXN Position: Q2 2020 in Review

HAP Trading sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 11,087 shares — an estimated $996K sold.

HAP Trading first reported a position in ALXN in Q3 2013 and held it in 8 quarters. The position peaked at $25.2M in Q3 2013. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • HAP Trading reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • HAP Trading sold 11,087 Alexion Pharmaceuticals shares in Q2 2020, an estimated $996K.
  • HAP Trading first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 8 quarters.
  • HAP Trading's Alexion Pharmaceuticals position peaked at $25.2M in Q3 2013.
  • 705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on HAP Trading's 13F filing for Q2 2020, filed 10 Aug 2020.